Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

17.0%

9 terminated/withdrawn out of 53 trials

Success Rate

55.0%

-31.5% vs industry average

Late-Stage Pipeline

1 trials in Phase 3/4

Results Transparency

127%

14 of 11 completed trials have results

Key Signals

12 recruiting14 with results5 withdrawn

Enrollment Performance

Analytics

Phase 2

26(49.1%)

Phase 1

19(35.8%)

N/A

5(9.4%)

Early Phase 1

2(3.8%)

Phase 3

1(1.9%)

53Total

Phase 2(26)

Phase 1(19)

N/A(5)

Early Phase 1(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (53)

Showing 20 of 53 trials

NCT05318469Phase 1Recruiting

Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

Role: collaborator

NCT04003649Phase 1Active Not Recruiting

IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM

Role: collaborator

NCT03587740Phase 2Active Not Recruiting

ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer

Role: collaborator

NCT04898894Phase 1Active Not Recruiting

Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Role: collaborator

NCT05101551Phase 1Recruiting

Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

Role: collaborator

NCT07434843Phase 2Recruiting

PH 2 Pemigatinib in SDH-deficient GIST

Role: collaborator

NCT06200155Phase 2Recruiting

Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy

Role: collaborator

NCT05053750Early Phase 1Active Not Recruiting

TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Role: collaborator

NCT02754752Phase 2Active Not Recruiting

Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment

Role: collaborator

NCT05669846Phase 2Recruiting

Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

Role: collaborator

NCT02482376Phase 2Active Not Recruiting

Preoperative Single-Fraction Radiotherapy in Early Stage Breast Cancer

Role: collaborator

NCT07021989Phase 2Not Yet Recruiting

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma